Generalized Myasthenia Gravis
Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skeletal muscles, including the muscles of arms and legs, leading to breathing difficulty and mobility issues. When the muscles affected are from multiple muscle groups throughout the body, it is called generalized myasthenia gravis (gMG).
With a higher diagnosed prevalence of generalized Myasthenia Gravis in the United States of approximately 32,188 cases, gMG has an equal prevalent ratio in males and females.
The newsletter by DelveInsight offers a crisp overview of the indication, its subtypes and symptoms. It also brings into focus the epidemiological trends segmented into geographies in the 7MM, ethnicity, gender, total and diagnosed cases.
As per DelveInsight assessments, the market size of generalized Myasthenia Gravis (gMG) in the 7MM was found to USD 2,602 million in 2017. The newsletter aims to help its clients and readers to gain insights into market trends and the pipeline therapies that shall veer the gMG market into a positive direction.
For rich insights into Generalized Myasthenia Gravis market landscape fill the form and get the newsletter rights into your inbox.
Escape the hassle of filling the forms every time by subscribing to our emailer's list and get all the updates and trends in the pharma industry into your inbox.
Stay Connected.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Market insights
- Latest News
- R&D in the field
- Upcoming Conferences
- Support from International organizations
